Weren't we all having a discussion on gaps closing or not?Most...

Weren't we all having a discussion on gaps closing or not?



Most recent gap has closed.

Simple fact is, this is not moving north past .05c until a product contract for Febridx comes out with a substantial order figure, or revenues jump substantially.

I would take everything the company says moving forward with a massive grain of salt as their "bullish" outlook and "ramping product sales" is yet to be seen.

Products since Covid are yet to break $1Million a quarter. Collectively each year, sure, but given the "delayed flu season" nature that the US seems to always have, then the December quarter will always show as a rubbish quarter and March likely to show a higher figure. I doubt though we will see a similar 200% increase on PCP for March quarter as that was $700K, are we really likely to see $2M+? Until CLIA waiver is received, this is going to be slow going and potential for a CR could occur, that is more so coupled by the delay in Hologic completion.

Does anyone have a range of questions we can email IR today for the webinar tomorrow?

1. What is the likelihood of a CR in coming months given the delay in Hologic FFN completion, lower services revenues and minimal product revenues? Whilst revenues increased on the PCP (which was low also), the incoming doesn't reflect a positive cash flow position and there appears to be low cash on hand for remaining quarters. Is this company banking on the CLIA waiver funds from BARDA to float other ongoing business requirements in the interim?

2. If there was a delay in Hologic FFN agreements being completed, why wasn't this highlighted earlier than the quarterly? The market didn't agree with the reporting coming out given a reduction in the "recognised revenue".

3. Will there be announcements when the CLIA patient milestones are received to ensure the market is seeing progress with the study?